Clinical Trial Update: A Study to Investigate the Effects and Safety of SPG601 for the Treatment of Fragile X Syndrome in Male Participants [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes SPG601 being studied for Fragile X syndrome in male participants, currently in Phase 2/3 and not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• SPG601 (SPG601)

Snippet

Sponsor: Spinogenix | Conditions: Fragile X Syndrome (FXS) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING